Search This Blog

Thursday, January 16, 2020

Durect shares halted for Ad Com meeting

Nasdaq has suspended trading in DURECT (NASDAQ:DRRX) pending the release of news, in this case, the outcome of an FDA advisory committee meeting today on bupivacaine extended-release solution for post-surgical analgesia.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)